Varicella Zooster IgM

Bacterial/ Viral

Report in 48Hrs

At Home

No Fasting Required

Details

Detects IgM antibodies against VZV, the virus responsible for chickenpox and shingles

₹2,030₹3,383

40% OFF

Varicella Zoster IgM Test Information Guide

Why is it done?
- Test Purpose: Detects IgM antibodies to varicella zoster virus (VZV), which indicates acute or recent primary infection with chickenpox or herpes zoster (shingles).
- Primary Indications: Confirmation of acute varicella (chickenpox) infection when clinical presentation is unclear; confirmation of herpes zoster (shingles) in atypical presentations; diagnosis of VZV infection in immunocompromised patients; prenatal screening in pregnant women with chickenpox symptoms; identification of primary infection in patients with vesicular rash.
- Typical Timing: Performed during acute phase of infection, typically within 5-7 days of symptom onset; most useful during first 2 weeks of illness when IgM levels are highest; can be ordered as part of initial diagnostic workup for febrile rash; useful for serological confirmation when PCR or culture results are not available.
Normal Range
- Reference Range: Negative or <0.9 Index (varies by laboratory methodology); typically reported as negative/not detected or positive/detected; some labs use numerical index values or ratios.
- Negative Result: Index <0.9 or negative/not detected indicates absence of recent or acute VZV infection; suggests either no infection, vaccination immunity, past infection with residual IgG only, or testing done too late in infection when IgM has declined.
- Positive Result: Index ≥0.9 or positive/detected indicates acute or recent primary infection with varicella zoster virus; represents newly acquired infection or reactivation of latent infection.
- Borderline Values: Index 0.8-1.1 may require repeat testing or interpretation with clinical correlation; consider IgG testing and serial samples for equivocal results.
- Units of Measurement: Reported as Index value (typically 0-10 scale), Negative/Positive (qualitative), or mIU/mL (international units); varies by assay methodology (ELISA, CLIA, immunofluorescence).
Interpretation
- Positive IgM Result: Indicates acute or primary infection with VZV occurring within 1-2 weeks; suggests current active viral replication; in primary infection (varicella), positive IgM appears early; in herpes zoster (shingles/reactivation), IgM presence is less common but may occur in immunocompromised patients; requires clinical correlation with symptoms.
- Negative IgM Result: May indicate absence of recent infection, past infection with immunity, vaccination response, testing performed after IgM decline (>2 weeks into illness), or non-VZV etiology; consider IgG testing to determine if prior immunity exists.
- IgM + IgG Pattern: Both positive indicates acute primary infection; seen in acute chickenpox or first episode of herpes zoster.
- IgM Negative + IgG Positive Pattern: Indicates past infection or immunity (vaccination or prior chickenpox); typical for herpes zoster recurrence in immune individuals.
- Factors Affecting Results: Timing of specimen collection (IgM peaks 5-7 days after rash onset); immunocompromised status (delayed or absent IgM response); cross-reactivity with other herpes viruses; vaccination history; assay methodology variation between laboratories; rheumatoid factor may cause false positive results.
- Clinical Significance: Positive IgM confirms active viral infection requiring treatment considerations, isolation precautions for vulnerable populations, and investigation of contacts; particularly important in pregnant women (risk of congenital varicella syndrome), neonates, immunocompromised patients, and healthcare workers.
Associated Organs
- Primary System: Integumentary (skin) system; nervous system (peripheral and central); respiratory system; immune system.
- Associated Conditions - Acute Varicella: Primary chickenpox infection; congenital varicella syndrome (if maternal infection in first trimester); varicella pneumonitis; secondary bacterial skin infection; varicella encephalitis.
- Associated Conditions - Herpes Zoster: Reactivation of latent VZV; post-herpetic neuralgia; herpes zoster ophthalmicus; Ramsay Hunt syndrome; zoster meningoencephalitis; disseminated zoster in immunocompromised patients.
- Complications from Abnormal Results: Secondary bacterial superinfection of lesions leading to cellulitis or sepsis; permanent neurological damage from meningoencephalitis; blindness from herpes zoster ophthalmicus; severe pneumonitis in adults; vertical transmission to fetus causing congenital defects; disseminated infection in immunocompromised patients.
- High-Risk Populations: Pregnant women; neonates; immunocompromised patients (HIV/AIDS, on immunosuppressive therapy); elderly patients; patients with chronic medical conditions.
Follow-up Tests
- If IgM Positive: Varicella Zoster IgG testing to assess immune response and past exposure; PCR or viral culture from vesicular fluid for confirmation and typing; repeat serology in 2-4 weeks to document seroconversion if initially equivocal; liver function tests (ALT, AST) if hepatitis suspected; chest imaging if respiratory symptoms present; CSF analysis if meningitis/encephalitis suspected.
- If IgM Negative with Clinical Suspicion: Repeat IgM testing in 3-5 days if high clinical suspicion; perform VZV IgG and consider IgG avidity testing; direct PCR or viral culture from vesicular lesions; immunofluorescence testing on aspirated fluid; repeat serology 10-14 days later to document seroconversion.
- Recommended Complementary Tests: Varicella Zoster IgG (assess immunity status and distinguish primary from recurrent); VZV PCR (gold standard for detection, particularly useful in immunocompromised); Viral culture (isolates VZV, confirms diagnosis); Gram stain and culture of vesicular fluid (rule out bacterial superinfection); Complete blood count; Comprehensive metabolic panel.
- Monitoring Frequency: Acute infection requires initial assessment; follow-up serology in 2-4 weeks for confirmation if initial result was equivocal; pregnant women with confirmed VZV require close obstetric monitoring; immunocompromised patients may need more frequent assessment and PCR monitoring.
- Related Diagnostic Tests: Herpes Simplex Virus 1 & 2 IgM (differential diagnosis for vesicular rashes); Epstein-Barr Virus serology (differential for fever/rash); Cytomegalovirus serology (in immunocompromised); Skin biopsy with immunohistochemistry; Direct fluorescent antibody staining of lesions.
Fasting Required?
- Fasting Requirement: No fasting required. This is a serological blood test that measures IgM antibodies and does not require patients to fast prior to collection.
- Specimen Collection: Serum sample collected via venipuncture; typically 5-10 mL in SST or gold-top tube; specimen can be collected any time of day; no special preparation needed.
- Timing of Collection: Optimal collection within 5-7 days of rash onset for maximum IgM detection; can collect up to 2 weeks after symptom onset; later collection may result in false negatives as IgM declines.
- Medications to Avoid: No medications need to be withheld; antiviral therapy (acyclovir, valacyclovir) does not interfere with IgM detection; specimen collection can proceed regardless of current treatment.
- Other Preparation Instructions: Patient should remain seated for 5 minutes before collection; inform healthcare provider of immunosuppressive medications or conditions; document symptom onset date for proper result interpretation; notify laboratory if immunocompromised status for expedited processing; avoid contamination of sample; ensure proper specimen labeling with patient demographics and collection date/time.
- Transport and Storage: Specimen should be transported to laboratory within 24 hours; refrigerate at 2-8°C if delay expected; do not freeze specimen unless specifically instructed by laboratory; serum separator tubes should be allowed to clot for 30 minutes before centrifugation.

How our test process works!